Access to therapy is part of the protection of the constitutional order: Peter Bely spoke at the SPIEF session on intellectual property
28.02.2022
28.02.2022
Abiraterone-Promomed, used for the treatment of prostate cancer, has received a registration certificate, becoming the second drug in the Promomed Group's cancer portfolio.
.jpg)
Prostate cancer (prostate cancer) remains one of the most pressing problems affecting the health of older men today. Approaches to the treatment of this disease depend on the prevalence of the tumor process. Abiraterone-Promomed is a modern antiandrogenic drug used in the second line of hormone therapy for metastatic castration-resistant prostate cancer.
Forming a portfolio of medicines aimed at treating socially significant diseases, including cancer, is one of the most important tasks for Promomed Group as part of its strategy to solve global medical problems, save lives and significantly improve patient health. When introducing new drugs to the market, including generic drugs, the company offers patients effective and safe medicines due to the high quality of their substances, the manufacturability of production processes, and the highest quality control standards.
Abiraterone Promomed will be available in the form of tablets with a dosage of 250 mg, which corresponds to standard application schemes.
Like most medicines produced by Promomed Group, this drug is included in the list of VED.
Stay informed
Stay informed
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office